PDL BioPharma, Inc. (PDLI): Price and Financial Metrics


PDL BioPharma, Inc. (PDLI)

Today's Latest Price: $3.24 USD

0.01 (0.31%)

Updated Jun 2 6:55pm

Add PDLI to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 336 in Biotech

See all "A" rated Strong Buy stocks

PDLI Stock Summary

  • With a year-over-year growth in debt of -89.49%, Pdl Biopharma Inc's debt growth rate surpasses only 1.96% of about US stocks.
  • Over the past twelve months, PDLI has reported earnings growth of 219.95%, putting it ahead of 94.22% of US stocks in our set.
  • As for revenue growth, note that PDLI's revenue has grown -89% over the past 12 months; that beats the revenue growth of just 1.13% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to Pdl Biopharma Inc, a group of peers worth examining would be UUUU, ACB, TEUM, MARA, and TIGR.
  • Visit PDLI's SEC page to see the company's official filings. To visit the company's web site, go to www.pdl.com.
PDLI Daily Price Range
PDLI 52-Week Price Range

PDLI Stock Price Chart More Charts


PDLI Price/Volume Stats

Current price $3.24 52-week high $3.86
Prev. close $3.23 52-week low $2.06
Day low $3.15 Volume 388,000
Day high $3.25 Avg. volume 1,260,127
50-day MA $3.12 Dividend yield N/A
200-day MA $2.97 Market Cap 377.61M

PDL BioPharma, Inc. (PDLI) Company Bio


PDL BioPharma Inc. manages a portfolio of patents and royalty assets related to the humanization of monoclonal antibodies and the discovery of a new generation of targeted treatments for cancer and immunologic diseases. The company was founded in 1986 and is based in Incline Village, Nevada.

PDLI Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target:Forecasted Gain:
$3.24$0.11-96%

We started the process of determining a valid price forecast for Pdl Biopharma Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Pdl Biopharma Inc ranked in the 6th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. The most interesting components of our discounted cash flow analysis for Pdl Biopharma Inc ended up being:

  • Interest coverage, a measure of earnings relative to interest payments, is -13.47; that's higher than only 8.91% of US stocks in the Healthcare sector that have positive free cash flow.
  • Its compound free cash flow growth rate, as measured over the past 5.73 years, is -0.26% -- higher than only 6.69% of stocks in our DCF forecasting set.
  • The business' balance sheet reveals debt to be 3% of the company's capital (with equity being the remaining amount). Approximately only 10.15% of US stocks with free cash flow have a lower reliance on debt in their capital structure.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%-97%
1%-97%
2%-96%
3%-96%
4%-96%
5%-96%

IVC, PHG, CRY, LHCG, and TEVA can be thought of as valuation peers to PDLI, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.


PDLI Latest News Stream


Event/TimeNews Detail
Loading, please wait...

PDLI Latest Social Stream


Loading social stream, please wait...

View Full PDLI Social Stream

Latest PDLI News From Around the Web

Below are the latest news stories about Pdl Biopharma Inc that investors may wish to consider to help them evaluate PDLI as an investment opportunity.

Edited Transcript of PDLI earnings conference call or presentation 7-May-20 8:30pm GMT

Q1 2020 PDL BioPharma Inc Earnings Call

Yahoo | May 27, 2020

PDL BioPharma Completes Distribution of Evofem Biosciences Common Stock to PDL Stockholders

INCLINE VILLAGE, Nev., May 21, 2020 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) announces that it has completed its previously announced distribution of all of the Company's 13,333,334 shares of common stock of Evofem Biosciences, Inc. ("Evofem") (Nasdaq:…

PR Newswire | May 21, 2020

The Daily Biotech Pulse: Mixed Filgotinib Readout For Gilead-Galapagos, Akorn To File For Chapter 11, D-Day For Aquestive

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs on May 20.) ADC Therapeutics SA (NYSE: ADCT ) (went public May 15) Allogene Therapeutics Inc (NASDAQ: ALLO ) Ascendis Pharma A/S (NASDAQ: ASND ) (announced first-quarter results) Altimmune Inc (NASDAQ: ALT ) Biondvax Pharmaceuticals Ltd – ADR (NASDAQ: BVXV ) Cue Biopharma Inc (NASDAQ: CUE ) (reacted to first-quarter results) Evoke Pharma Inc (NASDAQ: EVOK ) (announced FDA's conditional approval for the brand name Gimoti for its nasal spray product candidate for the relief of symptoms in adult women with acute and recurrent diabetic gastroparesis) GENMAB A/S/S ADR (NASDAQ: GMAB ) I-Mab ADR (NASDAQ: IMAB ) Immunomedics, Inc. (NASDAQ: IMMU ) Intellia Th...

Benzinga | May 21, 2020

PDL BioPharma Declares Distribution Ratio for Dividend of Evofem Biosciences Common Stock to PDL Stockholders

INCLINE VILLAGE, Nev., May 18, 2020 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) announces the final distribution ratio for the previously announced distribution of all of the Company's 13,333,334 shares of common stock of Evofem Biosciences, Inc. ("Evofem")…

PR Newswire | May 18, 2020

PDL Biopharma Inc (PDLI) Q1 2020 Earnings Call Transcript

Please note that a slide presentation to accompany management's prepared remarks is available on the Investor Relations section of the PDL website at pdl.com. Joining me today from PDL are Dominique Monnet, President and CEO; and Ed Imbrogno, Vice President and Chief Financial Officer. Please turn to Slide 2, and let me remind you that during this call, management will be making forward-looking statements regarding the Company's financial performance and other matters and actual results may differ materially from those expressed in or implied by the forward-looking statements.

Yahoo | May 8, 2020

Read More 'PDLI' Stories Here

PDLI Price Returns

1-mo -5.81%
3-mo -10.00%
6-mo 9.83%
1-year 6.58%
3-year 32.24%
5-year -44.01%
YTD -0.15%
2019 11.90%
2018 5.84%
2017 29.25%
2016 -38.25%
2015 -48.60%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.9718 seconds.